Behavior-change giant Noom makes its biggest longevity venture yet, pairing habit coaching with prescription-grade therapies.
Leading behavior-change company Noom is known as the app that helps people rethink their relationship with food, habits and weight. But this week, the company made it clear it wants to be seen as something bigger, as it has finalized its acquisition of Tailor Made Compounding (TMC), a licensed 503A pharmacy operating in 46 states, including California. It is the company’s first major acquisition and, more importantly, its largest investment to date in healthy aging [1].
Noom is trying to move from being a digital weight-health platform into a broader preventive care business, one that blends coaching, prescriptions and personalized interventions under one roof.
As interest in peptide-based therapies and other age-related wellness tools grows, Noom is positioning itself at the intersection of consumer health, telemedicine and longevity.
Noom’s leadership is framing the move as a natural evolution. “Weight health is the entry point to preventive care – and foundational to healthy aging. But it’s not the endpoint. This acquisition continues Noom’s expansion into healthy aging, supporting Noom’s mission to empower everyone, everywhere to live better longer – every day,” said Geoff Cook, CEO of Noom.
Cook said that, following the acquisition, the company intends to diversify its medical offerings to include peptide-based therapies such as sermorelin and various healthy aging interventions, such as NAD+. He further explained that these additions are part of a broader strategy to expand the range of conditions the platform addresses, moving beyond its current focus on weight management and hormonal health.
In plain terms, Noom is betting that people who first come in for weight support may also want help with energy, recovery, metabolic health, hormone-related issues and other concerns that often sit under the very broad and increasingly commercial banner of healthy aging.
That is a meaningful shift. Weight management remains one of the most visible on-ramps into longevity, especially in a market now shaped by GLP-1s and rising consumer awareness around metabolic health. However, companies that want to stay relevant in the next phase of preventive care are under pressure to offer more than one condition, one drug or one app.
Why owning the pharmacy matters
The acquisition gives Noom direct access to pharmacy infrastructure rather than relying entirely on outside partners.
TMC is a compounding pharmacy, meaning it can prepare personalized medications and wellness formulations prescribed for individual patients. It serves more than 400 clinics and works with multiple telehealth partners, giving Noom both scale and operational reach from day one.
Cook argues that bringing that capability in-house is about control as much as expansion.
“Noom’s trusted brand and proven lifestyle platform drive high engagement, enabling superior outcomes,” Cook continued. “By pairing sustainable behavior change with prescription-grade catalysts, we make lasting change feel easy. TMC produces those catalysts. By bringing this capability in-house, we’re building the infrastructure to scale proactive care responsibly, grounded in quality, compliance, and long-term outcomes.”
In the longevity space, the excitement around peptides, NAD+ and other interventions often runs ahead of the evidence and sometimes ahead of the guardrails. By emphasizing compliance and long-term outcomes, Noom is trying to distinguish itself from the more chaotic corners of wellness and telehealth.
A crowded, fast-moving longevity lane
TMC’s formulary spans men’s and women’s health, weight management, healthy aging, supplements, cosmetics and IV therapy. It also includes therapies such as compounded NAD+, peptides including sermorelin, topical GHK-Cu, oxytocin and methylene blue.
Not all of these interventions carry the same level of clinical consensus, and some remain controversial or highly context-dependent. That is precisely why this deal is worth watching.
Noom is not just selling access to trendy compounds; it is trying to wrap them inside a familiar behavior-change platform that already has mainstream brand recognition. In a market crowded with longevity clinics, influencer-led protocols and direct-to-consumer hype, that could be a differentiator…if it can balance ambition with clinical discipline.
TMC will continue to operate as a wholly owned subsidiary under its current leadership team, led by CEO Ross Jordan. The pharmacy expanded its compounding facility in 2024, growing its footprint to more than 40,000 square feet and adding upgraded environmental controls and barcode-based inventory systems.
Ross Jordan, the CEO of Tailor Made Compounding, explained that his company was originally established to provide premium therapies designed to improve individual health and wellness. He noted that by partnering with Noom, Tailor Made Compounding can now incorporate these clinical treatments into a validated behavior-change system that prioritizes sustainable results.
Jordan further asserted that the synergy between medical intervention and habit science will foster a healthcare environment dedicated to personalized care and enduring success.
For longevity watchers, the bigger story here is the continued convergence of consumer behavior platforms and clinical intervention. The next generation of preventive care is unlikely to be built on drugs alone, nor on coaching alone. It will likely be a hybrid model: data, habit change, diagnostics, wearables and carefully selected therapies working together. That is the lane Noom wants to own.
The company says it expects to integrate TMC and expand into new areas of healthy aging later this summer. If it succeeds, this acquisition could mark a broader shift in how longevity reaches the mainstream: not as a niche biohacker pursuit, but as a more familiar, consumer-friendly system built around everyday health decisions and the infrastructure to support them.
[1] https://www.noom.com/in-the-news/noom-acquires-503a-pharmacy/
